Major Breakthrough in Gynecological Oncology! Academician Baofa Yu Announces New Non-Invasive Treatment Achievement for Cervical Cancer

30 Oct, 2025

A landmark advancement has been achieved in the field of gynecological oncology at our institute. The latest scientific research paper by Academician BaofaYu, President of Shandong Baofa Tumor Research Institute and Foreign Academician of the Russian Academy of Natural Sciences, and his team, titled "Hapten-Mediated Chemical Immune Therapy with Drug Administration into Cervical Cancer without Hysterectomy: Awakening Immune Cells for Immunotherapy," has been officially published in a renowned international surgical journal.

Based on extensive clinical data analysis, the paper demonstrates that the intratumoral injection of chemotherapeutic drugs combined with a hapten induces an acute immune response in cervical cancer lesions, further awakening immune cells. This Enhanced Intratumoral Chemotherapy (HEIC) offers a suitable potential treatment method for cervical cancer patients, achieving an effect akin to immunologic surgery without the need for cervical cancer surgery.

Cervical cancer is one of the common malignant tumors seriously threatening women's health, closely associated with persistent infection of high-risk human papillomavirus (HPV). Current standard clinical treatments often include hysterectomy, radiotherapy, and chemotherapy. While these methods can effectively control the disease, the organ function loss caused by surgery and the side effects of radiotherapy and chemotherapy profoundly impact patients' physical and mental health and quality of life.

This research by Academician BaofaYu's team, based on extensive clinical data analysis, innovatively adopts the technical approach of "intratumoral injection of chemotherapeutic drugs combined with a hapten." By directly targeting the lesion, this therapy successfully induces a strong acute immune response within the cervical cancer lesion tissue, effectively "awakening" the body's own immune cells, enabling them to precisely recognize and attack cancer cells. This non-surgical chemoimmunotherapy model, termed "Chemical Conization," shows excellent potential in treating early-stage cervical cancer and precancerous lesions.

Compared to traditional cervical conization surgery, this innovative technology offers significant advantages:

Organ Preservation: Fundamentally avoids hysterectomy, preserving crucial hope for women with fertility desires or those wishing to maintain organ integrity.

Minimally Invasive and Painless: The treatment process is completed solely through local injection, making it ultra-minimally invasive with minimal patient discomfort and a better experience.

Dual Efficacy: Not only can it effectively clear cancerous lesions, but research also indicates it can achieve HPV clearance, reducing the risk of recurrence at its root.